Antiemetic prophylaxis of cancer chemotherapy-induced nausea and vomiting with cinnarizine and lorazepam.
An oral combination of cinnarizine and lorazepam was studied for the prophylaxis of nausea and vomiting induced by strongly emetogenic cancer chemotherapy. 56% of 59 chemotherapy courses in 29 patients were completed without emesis. Of the 42 cisplatin-containing regimens, 52% were without vomiting and 62% free of nausea. A further 11 patients (17 courses) received non-cisplatin emetogenic chemotherapy. In this group full emetic control was achieved in 65% of the courses. Diarrhea in 4% of the courses was the only side effect of this new oral combination.
Wilder-Smith
C H
CH
Department of Medicine, Kantonsspital, St. Gallen, Switzerland.
Senn
H J
HJ
D000284:Administration, Oral; D000328:Adult; D000932:Antiemetics; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002936:Cinnarizine / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D010865:Pilot Projects; D011446:Prospective Studies; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000932:Antiemetics; D000970:Antineoplastic Agents; D002936:Cinnarizine; D008140:Lorazepam; D002945:Cisplatin